title: Resistance to the growth-promoting and metabolic effects of growth hormone in children with chronic liver disease.
abstract: Because growth failure is a frequent complication of chronic liver disease in childhood, we examined the growth hormone/insulin-like growth factor type I axis and its relationship to growth disturbances, nutritional status, and carbohydrate metabolism in nine children (2.1 to 18.6 years of age) with chronic cholestatic liver disease. Seven had cholestasis associated with splenomegaly and histologic findings of cirrhosis; two patients had Alagille syndrome. Stature was less than or equal to 15th percentile in all except the youngest subject and less than 5th percentile in five subjects. Ten-hour, nocturnal, integrated serum concentrations of growth hormone were considerably higher in patients with cholestasis than in control subjects (mean +/- SD) 9.7 +/- 3.8 vs 4.7 +/- 1.9 ng/ml; p less than 0.02). Serum concentrations of insulin-like growth hormone type I were less than 95th percentile confidence intervals for age- and sex-matched norms in five patients and at the lower limits of normal in the remaining four patients. Insulin sensitivity, determined with the minimal model intravenous glucose tolerance test, was not decreased in five patients despite elevated levels of circulating growth hormone. The estimated mean caloric and protein intake exceeded the recommended dietary allowance and the weight-for-height index was greater than 90% for six of nine patients. Triceps and subscapular skin-fold thicknesses, indicators of body fat stores, were greater than 25th percentile for five of nine and eight of nine patients, respectively, suggesting deficient lipolytic action of GH. We conclude that children with cholestatic liver disease have a resistance to the growth-promoting, diabetogenic, and lipolytic properties of growth hormone.
authors.affiliation: Division of Gastroenterology and Nutrition, Children's Hospital Research Foundation, Cincinnati, Ohio 45229.
authors.forename: J C
authors.initials: JC
authors.lastname: Bucuvalas
authors.forename: W
authors.initials: W
authors.lastname: Cutfield
authors.forename: J
authors.initials: J
authors.lastname: Horn
authors.forename: M A
authors.initials: MA
authors.lastname: Sperling
authors.forename: J E
authors.initials: JE
authors.lastname: Heubi
authors.forename: B
authors.initials: B
authors.lastname: Campaigne
authors.forename: S D
authors.initials: SD
authors.lastname: Chernausek
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D002780:Cholestasis, Intrahepatic / Q000150:complications / Q000378:metabolism; D002908:Chronic Disease; D005260:Female; D005951:Glucose Tolerance Test; D006130:Growth Disorders / Q000209:etiology* / Q000378:metabolism; D013006:Growth Hormone / Q000097:blood*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D008107:Liver Diseases / Q000150:complications* / Q000378:metabolism; D008297:Male; D009752:Nutritional Status; D013002:Somatomedins / Q000378:metabolism*
chemical_list: D013002:Somatomedins; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone